Blood disorders
Lymphoma in Hangzhou
杭州 淋巴瘤
8 hospitals in Hangzhou
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Hangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 67 papers led
- Second Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院International Medical Department visitor guide43 papers led
- 15 papers led
- 13 papers led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 4 papers led
Lymphoma in every city Hangzhou on the disease page, with the national map
open trials on lymphoma with a hospital in Hangzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Hangzhou as lead sponsor or study site. 40 of them are led by a hospital in Hangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingExploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07164560
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-02
- Posted
- Registry
- NCT07398963
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingThiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07416890
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07481669
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07538635
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingUltra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07554898
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer Hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07788118
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAn Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06487624
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Hangzhou, Yantai
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingRituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06832267
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06883526
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingOrelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07022223
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingThe Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07073833
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingOrelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07078500
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAI-assisted Diagnosis of Malignant Brain Tumors
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07198256
Age 18 years to 100 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou
- RecruitingA Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07376642
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingScreening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06314334
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingCD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
- Phase
- Early phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06346912
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingSequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-06
- Posted
- Registry
- NCT06464861
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOptimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06504940
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingComparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06520163
Age 18 years to 75 years (registered criteria)
Led by Affiliated People's Hospital of Ningbo University; 3 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06534762
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingA Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06554561
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06554600
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06556199
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06615193
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingTargeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
- Phase
- Early phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06633341
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06634589
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Hangzhou, Suzhou, Wenzhou
- RecruitingRLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06674096
Age 65 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingCD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06696846
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06707259
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
- Phase
- Early phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06716164
Age 19 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingVHAG in Treating R/R T-ALL/LBL
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06742463
Age 14 years to 74 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingThe Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT05741359
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
- Phase
- Phase 1
- Started
- 2023-10
- Posted
- Registry
- NCT05892718
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingSafety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
- Phase
- Early phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06120166
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of OR for Second-line Treatment of Refractory MZL
- Phase
- Phase 4
- Started
- 2023-01
- Posted
- Registry
- NCT06134284
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingClinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
- Phase
- Phase 1
- Started
- 2022-07
- Posted
- Registry
- NCT05472558
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOrelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05600660
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
- Phase
- Phase 1
- Started
- 2022-12
- Posted
- Registry
- NCT05659628
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Ningbo
- RecruitingZR2 Sequential Immunochemotherapy for Newly Treated MCL
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05992597
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingCD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
- Phase
- Early phase 1
- Started
- 2021-11
- Posted
- Registry
- NCT04662294
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04922567
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOrelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
- Phase
- Phase 2
- Started
- 2021-07
- Posted
- Registry
- NCT04961515
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05147467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
- Phase
- Early phase 1
- Started
- 2020-01
- Posted
- Registry
- NCT04227015
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingCD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2020-12
- Posted
- Registry
- NCT04661020
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingHEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
- Phase
- Not given
- Started
- 2026-03
- Posted
- Registry
- NCT07483749
Age 1 year to 21 years (registered criteria)
Led by Children's Hospital, Zhejiang University School of MedicineHangzhou
- Not yet recruitingGlofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase
- Not given
- Started
- 2026-06
- Posted
- Registry
- NCT07669194
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06879470
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingZanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06918015
Age 18 years to 80 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07032324
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingHomoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07159906
Age 18 years to 99 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Enrolling by invitationCord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06827782
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Hangzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Hangzhou Normal University杭州师范大学附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Children's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院 | none | none | none | none | none | none | none | 81 open | 1 | none | none | 5 | none | 7 | none | none | 5 | 2 | 8 | 41 open | none | 0 | none | 1 | none | none | none | 11 open | none | none | 2 | 3 | 313 open | 4 | none | none | none | none | none | 1 | 2 | 21 open | none | 0 | none | 0 | 74 open | none | 0 | none | none | none | 0 | 4 | none | none | none | 4 | 1 | none | none | |
| Chun'an First People's Hospital淳安县第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第一医院(浙江省中医院) | none | none | none | 29 | 50 | none | 49 | none | none | none | none | 2 | 1 | none | none | 2 | none | 241 open | none | 8 | none | 24 | none | 1 | none | none | none | 4 | none | none | none | 2 | none | 33 open | 1 | none | none | 1 | none | 1 | none | 1 | none | none | 2 | none | 2 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital, Chinese Medical University浙江中医药大学附属第一医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院 | 5 | 11 | 2588 open | 6514 open | 1272 open | 11514 open | 6412 open | 32 | none | 1 | none | 8 | 91 open | 51 open | 0 | 556 open | 513 open | 11 open | 14 | 6711 open | none | 4 | 1 | 1 | none | 3 | 2 | 01 open | none | 41 open | 2 | 21 | 17 | none | 4 | 1 | 0 | 4 | none | 5 | none | 2 | none | 0 | 2 | 0 | 2 | 01 open | 1 | 1 | 4 | 4 | none | 1 | none | none | 0 | none | none | none | none | |
| Fourth Affiliated Hospital of Zhejiang University浙江大学医学院附属第四医院 | none | none | 6 | none | 93 open | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | |
| Fourth Affiliated Hospital, Zhejiang University | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Cancer Hospital杭州市肿瘤医院 | 1 | 4 | none | none | 131 open | 11 open | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Children's Hospital杭州市儿童医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou First People's Hospital杭州市第一人民医院 | 8 | none | 67 | 11 | 51 | 231 open | 21 | 8 | none | 1 | none | 3 | 1 | none | none | 5 | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | 16 | 1 | none | none | none | none | 1 | none | 2 | none | 1 | none | 1 | 1 | none | 0 | none | none | none | 1 | none | none | none | none | none | none | 0 | none | none | none | |
| Hangzhou Fuyang District First People's Hospital杭州市富阳区第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Hospital, Zhejiang Chinese Medicine University | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Lin'an Traditional Chinese Medicine Hospital杭州市临安区中医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Linping District First People's Hospital杭州市临平区第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Red Cross Hospital杭州市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou TCM Hospital, Zhejiang Chinese Medical University杭州市中医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 14 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Third People's Hospital杭州市第三人民医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Women's Hospital杭州市妇科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Xixi Hospital杭州市西溪医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | 1 | none | none | none | none | none | none | none | none | none | |
| Jianggan District People's Hospital杭州市江干区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第二医院(浙江省新华医院) | none | none | none | none | none | none | none | none | none | none | none | 1 | 3 | none | 1 | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院 | 1 | 43 open | 689 open | 596 open | 11512 open | 665 open | 10931 open | 419 open | none | 1 | 0 | 16 | 5 | 3 | 0 | 52 open | none | none | 2 | 4320 open | none | none | none | 1 | none | 7 | none | 4 | 12 | 82 open | none | 368 open | 9 | 5 | 4 | 0 | none | 4 | none | 6 | none | 0 | 0 | 1 | 0 | 1 | 2 | none | none | 0 | none | none | 1 | 1 | none | 1 | 4 | 0 | none | none | none | |
| Shaoxing People's Hospital绍兴市人民医院 | none | none | none | 14 | 29 | 7 | none | 9 | none | none | none | 2 | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | 1 | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shulan Hangzhou Hospital树兰(杭州)医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Sir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院 | 4 | 1 | 833 open | 44 | 831 open | 29 | 491 open | 15 | none | none | none | 10 | 2 | none | none | 4 | none | none | none | 7 | none | none | none | 1 | none | none | 3 | 0 | none | none | none | 232 open | 11 | none | none | 1 | none | 0 | 1 | 0 | none | none | 0 | none | 1 | none | 3 | none | 0 | none | 1 | 0 | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第三医院(浙江省中山医院) | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tongde Hospital浙江省立同德医院 | 0 | none | none | 20 | none | none | none | none | none | none | none | 0 | 8 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Women's Hospital浙江大学医学院附属妇产科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | |
| Xiaoshan Traditional Chinese Medical Hospital杭州市萧山区中医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhejiang Cancer Hospital浙江省肿瘤医院 | 196 open | 506 open | 353 open | 10611 open | 2047 open | 232 open | 11015 open | 18 | 0 | none | none | 2 | 0 | 0 | none | 2 | none | 2 | 2 | 137 open | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Zhejiang Hospital浙江医院 | none | none | none | none | 31 | none | 6 | none | none | none | none | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 9 | 0 | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhejiang Hospital浙江医院 | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 02 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhejiang Provincial People's Hospital浙江省人民医院 | 4 | 4 | 119 | 38 | 691 open | 533 open | 741 open | 241 open | none | 0 | none | 4 | 0 | 1 | 0 | 10 | none | none | none | 151 open | none | none | none | none | none | none | none | 2 | none | none | none | 12 | 5 | 3 | none | none | none | 1 | none | 1 | none | 1 | none | 0 | 0 | none | 4 | none | none | none | 4 | 2 | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Hangzhou.
- Glioma 81 open
- Hepatoblastoma 1
- Osteosarcoma 5
- Neuroblastoma 7
- B-cell acute lymphoblastic leukaemia 5
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 8
- Lymphoma 41 open
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 1
- Myasthenia gravis 11 open
- Biliary atresia 2
- Coronary heart disease 3
- Congenital heart disease 313 open
- Scoliosis 4
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 2
- Fabry disease 21 open
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 74 open
- Niemann–Pick disease type C 0
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 4
- Leber hereditary optic neuropathy 4
- Majeed syndrome 1
- Stomach cancer 29
- Lung cancer 50
- Breast cancer 49
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Multiple myeloma 2
- Aplastic anaemia 241 open
- Lymphoma 8
- Haemophilia A 24
- Thrombotic thrombocytopenic purpura 1
- Myasthenia gravis 4
- Coronary heart disease 2
- Scoliosis 33 open
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Behçet disease 2
- IgA nephropathy 2
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 11
- Hepatocellular carcinoma 2588 open
- Stomach cancer 6514 open
- Lung cancer 1272 open
- Pancreatic cancer 11514 open
- Breast cancer 6412 open
- Glioma 32
- Retinoblastoma 1
- Osteosarcoma 8
- Gastrointestinal stromal tumour 91 open
- Neuroblastoma 51 open
- Ewing sarcoma 0
- Multiple myeloma 556 open
- B-cell acute lymphoblastic leukaemia 513 open
- Aplastic anaemia 11 open
- Haemophagocytic lymphohistiocytosis 14
- Lymphoma 6711 open
- Haemophilia A 4
- Atypical haemolytic uraemic syndrome 1
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 3
- IgG4-related disease 2
- Myasthenia gravis 01 open
- Wilson disease 41 open
- Biliary atresia 2
- Coronary heart disease 21
- Congenital heart disease 17
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 1
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 5
- Fabry disease 2
- Duchenne muscular dystrophy 0
- Behçet disease 2
- Alport syndrome 0
- IgA nephropathy 2
- Gaucher disease 01 open
- Niemann–Pick disease type C 1
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 4
- Hirschsprung disease 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 8
- Hepatocellular carcinoma 67
- Stomach cancer 11
- Lung cancer 51
- Pancreatic cancer 231 open
- Breast cancer 21
- Glioma 8
- Retinoblastoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 1
- Multiple myeloma 5
- Lymphoma 7
- Coronary heart disease 16
- Congenital heart disease 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Fabry disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 0
- Primary biliary cholangitis 1
- Leber hereditary optic neuropathy 0
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 43 open
- Hepatocellular carcinoma 689 open
- Stomach cancer 596 open
- Lung cancer 11512 open
- Pancreatic cancer 665 open
- Breast cancer 10931 open
- Glioma 419 open
- Retinoblastoma 1
- Chordoma 0
- Osteosarcoma 16
- Gastrointestinal stromal tumour 5
- Neuroblastoma 3
- Ewing sarcoma 0
- Multiple myeloma 52 open
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 4320 open
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 7
- Myasthenia gravis 4
- Moyamoya disease 12
- Wilson disease 82 open
- Coronary heart disease 368 open
- Congenital heart disease 9
- Scoliosis 5
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 6
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 2
- Osteogenesis imperfecta 0
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 1
- Hereditary angioedema 1
- Familial adenomatous polyposis 4
- Leber hereditary optic neuropathy 0
- Nasopharyngeal carcinoma 4
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 833 open
- Stomach cancer 44
- Lung cancer 831 open
- Pancreatic cancer 29
- Breast cancer 491 open
- Glioma 15
- Osteosarcoma 10
- Gastrointestinal stromal tumour 2
- Multiple myeloma 4
- Lymphoma 7
- Thrombotic thrombocytopenic purpura 1
- IgG4-related disease 3
- Myasthenia gravis 0
- Coronary heart disease 232 open
- Congenital heart disease 11
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 0
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 0
- Pompe disease 0
- Behçet disease 1
- IgA nephropathy 3
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Nasopharyngeal carcinoma 196 open
- Oesophageal squamous cell carcinoma 506 open
- Hepatocellular carcinoma 353 open
- Stomach cancer 10611 open
- Lung cancer 2047 open
- Pancreatic cancer 232 open
- Breast cancer 11015 open
- Glioma 18
- Hepatoblastoma 0
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 0
- Multiple myeloma 2
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 137 open
- Fanconi anaemia 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 4
- Oesophageal squamous cell carcinoma 4
- Hepatocellular carcinoma 119
- Stomach cancer 38
- Lung cancer 691 open
- Pancreatic cancer 533 open
- Breast cancer 741 open
- Glioma 241 open
- Retinoblastoma 0
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 10
- Lymphoma 151 open
- Myasthenia gravis 2
- Coronary heart disease 12
- Congenital heart disease 5
- Scoliosis 3
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 0
- IgA nephropathy 4
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 2
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Hangzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.